XORTX to focus on late stage allopurinol intolerant gout program; discussion with FDA planned for first half 2025 regarding ...

This new study not only clarifies the causes of gout but also helps scientists explore more treatment options. Existing drugs ...

It has been awarded a fast-track review by the FDA, which Sobi said “underscores the urgent need for new treatment options for patients with chronic refractory gout.” If approved, it will ...

Gout tophi totally disappeared and renal function remained stable. The patient continues to receive rasburicase treatment. P Richette is a Rheumatologist and T Bardin is a Professor of ...

Better treatment of gout will mean that fewer patients will be subject to long-term treatment with NSAIDs or prednisone, with associated benefits in blood pressure, diabetes and renal function.